{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:36:15Z","timestamp":1792650975868,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY026682, R01EY024665, R01EY025225, R01EY024698, R01EY03195201, and P30EY026877"],"award-info":[{"award-number":["R01EY026682, R01EY024665, R01EY025225, R01EY024698, R01EY03195201, and P30EY026877"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["F30EYE027986 and T32GM007337"],"award-info":[{"award-number":["F30EYE027986 and T32GM007337"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Cancer League"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1186\/s12943-021-01336-4","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T04:15:55Z","timestamp":1614140155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk"],"prefix":"10.1186","volume":"20","author":[{"given":"Gabriel","family":"Velez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teja","family":"Chemudupati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie A.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Toral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-1741","authenticated-orcid":false,"given":"Vinit B.","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"issue":"9","key":"1336_CR1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881\u20135.","journal-title":"Ophthalmology"},{"key":"1336_CR2","first-page":"805","volume-title":"AJCC cancer staging manual","author":"T Kivel\u00e4","year":"2016","unstructured":"Kivel\u00e4 T, Simpson RE, Grossniklaus HE. Uveal melanoma. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing; 2016. p. 805\u201317.","edition":"8"},{"issue":"2","key":"1336_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/IAE.0000000000001757","volume":"38","author":"MI Seider","year":"2018","unstructured":"Seider MI, Mruthyunjaya P. Molecular prognostics for uveal melanoma. Retina. 2018;38(2):211\u20139.","journal-title":"Retina"},{"issue":"8","key":"1336_CR4","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","volume":"119","author":"MD Onken","year":"2012","unstructured":"Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596\u2013603.","journal-title":"Ophthalmology"},{"key":"1336_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ajo.2018.07.045","volume":"195","author":"L Cai","year":"2018","unstructured":"Cai L, Paez-Escamilla M, Walter SD, Tarlan B, Decatur CL, Perez BM, Harbour JW. Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma. Am J Ophthalmol. 2018;195:154\u201360.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1336_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/tvst.7.5.12","volume":"7","author":"G Velez","year":"2018","unstructured":"Velez G, Tang PH, Cabral T, Cho GY, Machlab DA, Tsang SH, Bassuk AG, Mahajan VB. Personalized proteomics for precision health: identifying biomarkers of vitreoretinal disease. Transl Vis Sci Technol. 2018;7(5):12.","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"1336_CR7","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016;22(5):1234\u201342.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1336_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2353\/jmoldx.2010.090220","volume":"12","author":"MD Onken","year":"2010","unstructured":"Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12(4):461\u20138.","journal-title":"J Mol Diagn"},{"issue":"1","key":"1336_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41467-019-14256-1","volume":"11","author":"MA Durante","year":"2020","unstructured":"Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS, Harbour JW. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 2020;11(1):496.","journal-title":"Nat Commun"},{"issue":"4","key":"1336_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/bjophthalmol-2015-306921","volume":"100","author":"AD Singh","year":"2016","unstructured":"Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016;100(4):456\u201362.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1336_CR11","first-page":"855","volume":"152","author":"MJ Hendrix","year":"1998","unstructured":"Hendrix MJ, Seftor EA, Seftor RE, Kirschmann DA, Gardner LM, Boldt HC, Meyer M, Pe'er J, Folberg R. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor\/scatter factor (HGF\/SF). Am J Pathol. 1998;152(4):855\u201363.","journal-title":"Am J Pathol"},{"issue":"4","key":"1336_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/bjc.2016.419","volume":"116","author":"A Daud","year":"2017","unstructured":"Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017;116(4):432\u201340.","journal-title":"Br J Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01336-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-021-01336-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01336-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T04:16:52Z","timestamp":1614140212000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-021-01336-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1186\/s12943-021-01336-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739655955.793584565","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Stanford University Institutional Review Board (IRB)\/Ethics Committee and adhered to the tenets set forth in the Declaration of Helsinki. All participants provided written informed consent. Data were collected and analyzed from November 2018 to March 2020.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}